Interesting take, I think we have been saying for over a year the J&J market was beating a dead horse and all the silly projections the DECNers and Bozo berman put out there was BS.
As an investor, you should be interested in the market cap of DECN, right. As well as eventual share price. The amount of money Bozo Berman needs to distribute any product will be highly dilutive, so investments in DECN on a stock level is a joke. Without audited financials, there will be no serious investors.
Having approved FDA products is great, and that is the only thing I would give Bozo Berman good grades on, but what good is it if there are pathetic sales.
Stock investors are pretty much screwed here. Maybe if your cost is .02 you might make a few bucks, even then I doubt it.
News 
Market Data 
Discover 
